In conclusion, this study provides a new mechanistic insight linking matrix stiffness-YAP-ACADL axis to lipid metabolic reprogramming and HCC progression, indicating that the ACADL-dependent mechanoresponsive pathway is a potential therapeutic target for HCC treatment (Figure 8G). The gene discussed is ACADL; the disease is hepatocellular carcinoma.